Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances

Intellia Therapeutics outlined potential launch preparations for lonvo-z, its hereditary angioedema treatment, at a Morgan Stanley event. Management also highlighted the ongoing Phase III program in transthyretin amyloidosis and discussed its capital position, signaling continued advancement of its clinical pipeline but providing no new efficacy, regulatory, or financial figures.